Scholarlink

Purpose of Review <p>Summarize and update the most recent evidence on biomarkers of immunotherapy response in breast cancer including currently used and investigational markers.</p> Recent Findings <p>Currently, immune checkpoint inhibitors (ICIs) are approved only for patients with triple negative breast cancers (TNBC); however, ICIs are actively investigated in all breast cancer subtypes. Because only a subset of patients derives clinical benefit from ICIs, predictive biomarkers are crucial for rational treatment selection. In metastatic TNBC, PD-L1 positivity of the tumor and/or immune cells defines the patient population eligible for ICI therapy; however, it is an imperfect biomarker, and its expression does not always correlate with ICI benefit. Other biomarkers such as high tumor mutation burden (TMB) and microsatellite instability (MSI)-High status also serve as tumor-agnostic indicators of ICI response. In early-stage TNBC, ICI benefit appears to be independent of PD-L1 expression. Higher tumor infiltrating lymphocytes (TILs) are generally associated with improved ICI responses. Gene expression signatures are emerging as novel predictors of ICI response.</p> Summary <p>The indications for ICIs in breast cancer are rapidly increasing. Currently available biomarkers fall short of accurately predicting which patients will benefit most from ICI therapy, highlighting the need for further research for more rational selection of patients to maximize efficacy and limit toxicities. </p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Emerging Biomarkers to Predict Immunotherapy Response in Breast Cancer

  • 期刊论文

  • 发表日期：

    2025年9月20日

查看全文
  • Hannah Maynard,
  • Daisong Liu,
  • Julia Foldi

摘要

Purpose of Review

Summarize and update the most recent evidence on biomarkers of immunotherapy response in breast cancer including currently used and investigational markers.

Recent Findings

Currently, immune checkpoint inhibitors (ICIs) are approved only for patients with triple negative breast cancers (TNBC); however, ICIs are actively investigated in all breast cancer subtypes. Because only a subset of patients derives clinical benefit from ICIs, predictive biomarkers are crucial for rational treatment selection. In metastatic TNBC, PD-L1 positivity of the tumor and/or immune cells defines the patient population eligible for ICI therapy; however, it is an imperfect biomarker, and its expression does not always correlate with ICI benefit. Other biomarkers such as high tumor mutation burden (TMB) and microsatellite instability (MSI)-High status also serve as tumor-agnostic indicators of ICI response. In early-stage TNBC, ICI benefit appears to be independent of PD-L1 expression. Higher tumor infiltrating lymphocytes (TILs) are generally associated with improved ICI responses. Gene expression signatures are emerging as novel predictors of ICI response.

Summary

The indications for ICIs in breast cancer are rapidly increasing. Currently available biomarkers fall short of accurately predicting which patients will benefit most from ICI therapy, highlighting the need for further research for more rational selection of patients to maximize efficacy and limit toxicities.